These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38747068)

  • 1. Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.
    Liu S; Gou H; Wei H; Chen S; Zhuo S; Luo M; Qin S; Zhang M; Chen J; Huang Z; Xia X; Yang X; He K
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1684-1694. PubMed ID: 38747068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged survival of human hepatocarcinoma cells in the liver of newborn C57BL/6 mice and resulting cellular xenorejection, especially the activation of hepatic natural killer T cells.
    Du X; Bai Z; Zhang J; Liu L; Han Y; Wang Z; Huan T; Wu B
    Pathobiology; 2010; 77(3):115-28. PubMed ID: 20516727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
    Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
    Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing NKT cell-mediated immunity against hepatocellular carcinoma: Role of XYXD in promoting primary bile acid synthesis and improving gut microbiota.
    Deng Z; Ouyang Z; Mei S; Zhang X; Li Q; Meng F; Hu Y; Dai X; Zhou S; Mao K; Huang C; Dai J; Yi C; Tan N; Feng T; Long H; Tian X
    J Ethnopharmacol; 2024 Jan; 318(Pt B):116945. PubMed ID: 37490989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
    Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
    Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies.
    Debray D; Rainteau D; Barbu V; Rouahi M; El Mourabit H; Lerondel S; Rey C; Humbert L; Wendum D; Cottart CH; Dawson P; Chignard N; Housset C
    Gastroenterology; 2012 Jun; 142(7):1581-91.e6. PubMed ID: 22370478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.
    Ma C; Han M; Heinrich B; Fu Q; Zhang Q; Sandhu M; Agdashian D; Terabe M; Berzofsky JA; Fako V; Ritz T; Longerich T; Theriot CM; McCulloch JA; Roy S; Yuan W; Thovarai V; Sen SK; Ruchirawat M; Korangy F; Wang XW; Trinchieri G; Greten TF
    Science; 2018 May; 360(6391):. PubMed ID: 29798856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
    Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy.
    Tanimine N; Tanaka Y; Kobayashi T; Tashiro H; Miki D; Imamura M; Aikata H; Tanaka J; Chayama K; Ohdan H
    Cancer Immunol Res; 2014 Dec; 2(12):1142-7. PubMed ID: 25135909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
    Li HH; Wang J; Duan ZH; Zhang HW; Chen JS
    Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):558-61. PubMed ID: 15555289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments.
    Lee IC; Huang YH; Chau GY; Huo TI; Su CW; Wu JC; Lin HC
    Int J Cancer; 2013 Dec; 133(12):2895-902. PubMed ID: 23749461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection.
    Liao BY; Wang Z; Hu J; Liu WF; Shen ZZ; Zhang X; Yu L; Fan J; Zhou J
    Tumour Biol; 2016 Mar; 37(3):2987-98. PubMed ID: 26415733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
    J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis.
    Yang H; Yang Y; Dou J; Cui R; Cheng Z; Han Z; Liu F; Yu X; Zhou X; Yu J; Liang P
    Cancer Biol Med; 2020 May; 17(2):478-491. PubMed ID: 32587783
    [No Abstract]   [Full Text] [Related]  

  • 15. The influences of cholecystectomy on the circadian rhythms of bile acids as well as the enterohepatic transporters and enzymes systems in mice.
    Zhang F; Duan Y; Xi L; Wei M; Shi A; Zhou Y; Wei Y; Wu X
    Chronobiol Int; 2018 May; 35(5):673-690. PubMed ID: 29381405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and Implications of Natural Killer and Natural Killer T Cells in Hepatocellular Carcinoma.
    Zahran AM; Abdel-Meguid MM; Ashmawy AM; Rayan A; Elkady A; Elsherbiny NM; Hetta HF
    Egypt J Immunol; 2018 Jun; 25(2):45-52. PubMed ID: 30600947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy.
    Wu J; Du J; Liu L; Li Q; Rong W; Wang L; Wang Y; Zang M; Wu Z; Zhang Y; Qu C
    PLoS One; 2012; 7(12):e50035. PubMed ID: 23227158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy.
    Wubetu GY; Utsunomiya T; Ishikawa D; Yamada S; Ikemoto T; Morine Y; Iwahashi S; Saito Y; Arakawa Y; Imura S; Kanamoto M; Zhu C; Bando Y; Shimada M
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S721-8. PubMed ID: 24965572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection.
    Kawaguchi Y; Sakamoto Y; Ito D; Ito K; Arita J; Akamatsu N; Kaneko J; Hasegawa K; Moriya K; Kokudo N
    Biosci Trends; 2017 Nov; 11(5):574-580. PubMed ID: 29081488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.